On Wednesday, U.S. drugmaker Pfizer Inc. mentioned plans to shut down two manufacturing plants in India. Pfizer had acquired the sites as part of its $15 billion purchase of Hospira Inc. in 2015.
The factories, which produce generic injectables like penicillin, employs around 1,700 workers in the states of Tamil Nadu and Maharashtra. The pharma company cited “significant long term loss of product demand” as the reason behind the decision to close the plants. These plants do not make products for the India market.
Additionally, Pfizer is shuttering a Hospira research and development lab in the Indian city Chennai, but spokesman Steven Danehy said that that was unrelated to the shutdown of the aforementioned two plants.
Pfizer also mentioned that it is expanding operations in its Visakhapatnam facility in south India.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in of 279 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 06, 2025. You may want to consider a long position or call options on PFE as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on November 06, 2025. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
PFE moved above its 50-day moving average on November 06, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PFE crossed bullishly above the 50-day moving average on November 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for PFE moved out of overbought territory on November 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where PFE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on November 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating for company is (best 1 - 100 worst), which means the company is slightly undervalued. The valuation of the company is based on a proprietary formula which takes into account a set of fundamentals and gives us an estimate of the price per share for the company. We then compare this estimate with the current price per share. As a result, this company is rated as undervalued in the industry. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.524) is normal, around the industry mean (8.828). P/E Ratio (14.465) is within average values for comparable stocks, (23.985). PFE's Projected Growth (PEG Ratio) (13.685) is very high in comparison to the industry average of (2.041). PFE's Dividend Yield (0.069) is considerably higher than the industry average of (0.027). P/S Ratio (2.262) is also within normal values, averaging (3.575).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor